Hypovitaminosis D in Primary Hyperparathyroidism: to Treat or Not to Treat? That is the Question

Overview

Journal J Endocrinol Invest

Publisher Springer

Specialty Endocrinology

Date 2014 Mar 21

PMID 24647989

Citations 4

Authors

Salvatore Minisola

Elisabetta Romagnoli

Alfredo Scillitani

Sudhakar D Rao

Affiliations

Soon will be listed here.

Citing Articles

Vitamin D Increases Irisin Serum Levels and the Expression of Its Precursor in Skeletal Muscle.

Sanesi L, Dicarlo M, Pignataro P, Zerlotin R, Pugliese F, Columbu C Int J Mol Sci. 2023; 24(4).

PMID: 36835539 PMC: 9963830. DOI: 10.3390/ijms24044129.

Changes in bone mineral density after parathyroidectomy in patients with moderate to severe primary hyperparathyroidism.

Lu S, Gong M, Zha Y, Cui A, Chen C, Yang H J Int Med Res. 2020; 48(10):300060520964698.

PMID: 33135515 PMC: 7780563. DOI: 10.1177/0300060520964698.

A reappraisal of vitamin D effect on non-skeletal targets and mortality.

Minisola S, Cipriani C, Cilli M, Scillitani A, Pepe J J Endocrinol Invest. 2015; 38(11):1239-41.

PMID: 26359144 DOI: 10.1007/s40618-015-0387-3.

Italian Society of Endocrinology Consensus Statement: definition, evaluation and management of patients with mild primary hyperparathyroidism.

Marcocci C, Brandi M, Scillitani A, Corbetta S, Faggiano A, Gianotti L J Endocrinol Invest. 2015; 38(5):577-93.

PMID: 25820553 DOI: 10.1007/s40618-015-0261-3.

References

Carnevale V, Manfredi G, Romagnoli E, De Geronimo S, Paglia F, Pepe J . Vitamin D status in female patients with primary hyperparathyroidism: does it play a role in skeletal damage?. Clin Endocrinol (Oxf). 2003; 60(1):81-6. DOI: 10.1111/j.1365-2265.2004.01946.x. View

Romagnoli E, Pepe J, Piemonte S, Cipriani C, Minisola S . Management of endocrine disease: value and limitations of assessing vitamin D nutritional status and advised levels of vitamin D supplementation. Eur J Endocrinol. 2013; 169(4):R59-69. DOI: 10.1530/EJE-13-0435. View

Silverberg S, Shane E, Dempster D, Bilezikian J . The effects of vitamin D insufficiency in patients with primary hyperparathyroidism. Am J Med. 2000; 107(6):561-7. DOI: 10.1016/s0002-9343(99)00294-6. View

Rao D . Perspective on assessment of vitamin D nutrition. J Clin Densitom. 2000; 2(4):457-64. DOI: 10.1016/s1094-6950(06)60411-3. View

Stein E, Dempster D, Udesky J, Zhou H, Bilezikian J, Shane E . Vitamin D deficiency influences histomorphometric features of bone in primary hyperparathyroidism. Bone. 2010; 48(3):557-61. PMC: 3039097. DOI: 10.1016/j.bone.2010.10.004. View

Shah V, Shah C, Bhadada S, Rao D . Effect of 25 (OH) D replacements in patients with primary hyperparathyroidism (PHPT) and coexistent vitamin D deficiency on serum 25(OH) D, calcium and PTH levels: a meta-analysis and review of literature. Clin Endocrinol (Oxf). 2014; 80(6):797-803. DOI: 10.1111/cen.12398. View

Zierold C, Mings J, Deluca H . Regulation of 25-hydroxyvitamin D3-24-hydroxylase mRNA by 1,25-dihydroxyvitamin D3 and parathyroid hormone. J Cell Biochem. 2003; 88(2):234-7. DOI: 10.1002/jcb.10341. View

Rolighed L, Rejnmark L, Sikjaer T, Heickendorff L, Vestergaard P, Mosekilde L . Vitamin D treatment in primary hyperparathyroidism: a randomized placebo controlled trial. J Clin Endocrinol Metab. 2014; 99(3):1072-80. DOI: 10.1210/jc.2013-3978. View

Bollerslev J, Marcocci C, Sosa M, Nordenstrom J, Bouillon R, Mosekilde L . Current evidence for recommendation of surgery, medical treatment and vitamin D repletion in mild primary hyperparathyroidism. Eur J Endocrinol. 2011; 165(6):851-64. DOI: 10.1530/EJE-11-0589. View

10.

Tucci J . Vitamin D therapy in patients with primary hyperparathyroidism and hypovitaminosis D. Eur J Endocrinol. 2009; 161(1):189-93. DOI: 10.1530/EJE-08-0901. View

11.

Moosgaard B, Vestergaard P, Heickendorff L, Melsen F, Christiansen P, Mosekilde L . Vitamin D status, seasonal variations, parathyroid adenoma weight and bone mineral density in primary hyperparathyroidism. Clin Endocrinol (Oxf). 2005; 63(5):506-13. DOI: 10.1111/j.1365-2265.2005.02371.x. View

12.

Rathi M, Gonzalez S, Wright D, Ellis N, Peacey S . Management of hypovitaminosis D in patients with primary hyperparathyroidism. J Endocrinol Invest. 2014; 37(5):467-71. DOI: 10.1007/s40618-014-0056-y. View

13.

Minisola S, Scarnecchia L, Scarda A, Bigi F, Tabolli S, Valtorta C . Serum osteocalcin in primary hyperparathyroidism: short-term effect of surgery. Miner Electrolyte Metab. 1988; 14(4):201-7. View

14.

Clements M, Davies M, Fraser D, LUMB G, Mawer E, Adams P . Metabolic inactivation of vitamin D is enhanced in primary hyperparathyroidism. Clin Sci (Lond). 1987; 73(6):659-64. DOI: 10.1042/cs0730659. View

15.

Isidro M, Ruano B . Biochemical effects of calcifediol supplementation in mild, asymptomatic, hyperparathyroidism with concomitant vitamin D deficiency. Endocrine. 2009; 36(2):305-10. DOI: 10.1007/s12020-009-9211-1. View

16.

Rao D, Honasoge M, Divine G, Phillips E, Lee M, Ansari M . Effect of vitamin D nutrition on parathyroid adenoma weight: pathogenetic and clinical implications. J Clin Endocrinol Metab. 2000; 85(3):1054-8. DOI: 10.1210/jcem.85.3.6440. View

17.

Minisola S, Romagnoli E, Scarnecchia L, Rosso R, Pacitti M, Scarda A . Serum carboxy-terminal propeptide of human type I procollagen in patients with primary hyperparathyroidism: studies in basal conditions and after parathyroid surgery. Eur J Endocrinol. 1994; 130(6):587-91. DOI: 10.1530/eje.0.1300587. View

18.

Grey A, Lucas J, Horne A, Gamble G, Davidson J, Reid I . Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency. J Clin Endocrinol Metab. 2005; 90(4):2122-6. DOI: 10.1210/jc.2004-1772. View